The Global Hypertension and Heart Failure Treatment for Covid-19 2020 Market Research Report Is a skilled and in-depth study on the present state of Hypertension and Heart Failure Treatment for Covid-19 Market. This report studies the Hypertension and Heart Failure Treatment for Covid-19 market with Many details of the industry like the market size, market status, marketplace trends and prediction, the report also provides brief information of their competitors as well as the specific growth opportunities with key market drivers. Find the complete Hypertension and Heart Failure Treatment for Covid-19 market analysis segmented by firms, area, type and software in the document. Continue reading →

A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Hypertension and Heart Failure Drugs Market. On the basis of historic growth analysis and current scenario of Hypertension and Heart Failure Drugs market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Continue reading →

Middle-aged and older women who lacked social ties were much more likely than men to suffer from hypertension and stroke, warn researchers. In a study, published in the Journal of Hypertension, the research team discovered that social isolation affects the health of men and women in different ways including placing women at higher risk of high blood pressure. Continue reading →

11/01/2020 | 01:35pm EST PUBLISHED30 October 2020 30 October 2020 07:00 GMT Agreement supports strategy of focusing on newer medicines in main therapy areas AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of hypertension. Continue reading →

Comprehensive quantitative and qualitative research on Hypertension Drugs Market. Continue reading →

The family of a fisheries observer who died onboard a Taiwanese ship earlier this year are demanding answers from authorities after the ship and its crew were released, and the cause of death changed from blunt force trauma to complications from hypertension. Continue reading →

Idiopathic Intracranial Hypertension Treatment Market Scope of the Report: The worldwide market for Idiopathic Intracranial Hypertension Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2018, according to a new study. This report focuses on the Idiopathic Intracranial Hypertension Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa Continue reading →